{
  "id": "601c33f81cb411341a000017",
  "type": "summary",
  "question": "What is the mechanisms of action of Evinacumab?",
  "ideal_answer": "Evinacumab is angiopoietin-like protein 3 (ANGPTL3) monoclonal antibody that was shown to substantially reduce low-density lipoprotein cholesterol concentration.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32841138",
    "http://www.ncbi.nlm.nih.gov/pubmed/33295805",
    "http://www.ncbi.nlm.nih.gov/pubmed/31578082",
    "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
    "http://www.ncbi.nlm.nih.gov/pubmed/31843957",
    "http://www.ncbi.nlm.nih.gov/pubmed/32492513",
    "http://www.ncbi.nlm.nih.gov/pubmed/32332430",
    "http://www.ncbi.nlm.nih.gov/pubmed/31008773",
    "http://www.ncbi.nlm.nih.gov/pubmed/32520777",
    "http://www.ncbi.nlm.nih.gov/pubmed/30403015",
    "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
    "http://www.ncbi.nlm.nih.gov/pubmed/28538136",
    "http://www.ncbi.nlm.nih.gov/pubmed/33196153",
    "http://www.ncbi.nlm.nih.gov/pubmed/30011918",
    "http://www.ncbi.nlm.nih.gov/pubmed/32511037",
    "http://www.ncbi.nlm.nih.gov/pubmed/31100030",
    "http://www.ncbi.nlm.nih.gov/pubmed/33278127",
    "http://www.ncbi.nlm.nih.gov/pubmed/31242752"
  ],
  "snippets": [
    {
      "text": "Evinacumab, a monoclonal antibody against ANGPTL3, has been shown to substantially reduce LDL-C of an average of 49%, independently of residual LDLR activity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32332430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Novel therapies, not dependent on a functioning LDLR include lomitapide and mipomersen, which decrease hepatic apolipoprotein B secretion, and evinacumab, directed at the angiopoietin like-3 protein (ANGPLT-3).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32520777",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Multiple ANGPLT3 inhibitors (evinacumab, IONIS-ANGPTL3-LRx, ARO-ANG3) effectuate TG reductions up to 70% with concomitant potent reduction in all other apoB containing lipoprotein fractions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511037",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, regarding TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492513",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocumab or evinacumab, monoclonal antibodies against cholesterol-regulating proprotein convertase subtilisin/kexin type 9 and angiopoietin-like protein 3, may provide more benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31843957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include an antisense oligonucleotide against apoC-III (volanesorsen), a monoclonal antibody against angiopoietin-like protein-3 (evinacumab), and other agents currently in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32841138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND AIMS: Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial hypercholesterolemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e I clinical trials with a monoclonal anti-ANGPTL3 antibody (evinacumab) and anti-sense oligonucleotide (ASO) clearly show a significant lipid lowering effect. In addition, from t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30011918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ease. A phase 2, proof-of-concept study (NCT02265952) demonstrated that evinacumab, a fully human monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein), reduced LDL-C levels in 9 patients with genotypically confirmed homozygous familial hypercholesterolemia and was well tolerated",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578082",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ng TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering. At least, using ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492513",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab is a monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3) and it seems that it can substantially lower elevated TGs levels because ANGPTL3 also regulates TGs metabolism.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30403015",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "fter an attentive literature search, the authors resumed here information on proprotein convertase subtilisin/kexin 9 inhibitors (evolocumab and alirocumab), small interfering RNA molecule inclisiran, antisense oligonucleotides (mipomersen, volanesorsen, ISIS 681257), and drugs targeting angiopoietin-like protein 3 (evinacumab, IONIS-ANGPTL3Rx).E",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31100030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Evinacumab, an ANGPTL3 inhibitor, reduced triglycerides in healthy human volunteers and in homozygous familial hypercholesterolemic individuals",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31242752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND AND AIMS: Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial hypercholesterolemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "her lipids. Evinacumab, an ANGPTL3 inhibitor, reduced triglycerides in healthy human volunteers and in homozygous familial hypercholesterolemic ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31242752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND AIMS: Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ar disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia.METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) ever",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "r disease. A phase 2, proof-of-concept study (NCT02265952) demonstrated that evinacumab, a fully human monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein), reduced LDL-C levels in 9 patients with genotypically confirmed homozygous familial hypercholesterolemia and was well",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578082",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "equire LDL receptor (LDLR) activity. Evinacumab, a novel monoclonal antibody against angiopoetin-like 3 (ANGPTL3), reduces LDL-C by 50% independent of LDLR activity.SUMMARY: Achieving a target LDL-C in familial hypercholesterolemia can be challenging with standard LLT; however, novel therapeutic modalities show remarkable reductions in LDL-C allowing nearly all patients with HeFH and a significant proportion of patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33278127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33196153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We also tested the effects of a human monoclonal antibody, evinacumab, against Angptl3 in dyslipidemic mice and against ANGPTL3 in healthy human volunteers with elevated levels of triglycerides or LDL cholesterol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538136",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}